#ENVB

2 months ago

Enveric Biosciences Announces Patent Issuance Enveric Biosciences (NASDAQ: ENVB) announced issuance of U.S. Patent No. 12,492,179 on December 29, 2025, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”The patent claims compositions and treatment methods for novel, potentially neuroplastogenic and non‑hallucinogenic molecules, expands the company’s pipeline of patent‑protected candidates, and provides composition‑of‑matter protection intended to strengthen licensing and partnership prospects in neuropsychiatric, neurological, and addiction disorders.

#ENVB Enveric Biosciences Announces Patent Issuance

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds Enveric Biosciences (NASDAQ: ENVB) announced definitive agreements for the immediate exercise of outstanding warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, generating expected gross proceeds of approximately $3.1 million (before fees and expenses).In connection with the exercises, the company will issue new unregistered Series E and Series F warrants (each to purchase up to 426,390 shares) with exercise price $7.05; Series E expires five years after the resale registration effective date and Series F expires 18 months after that date. The offering is expected to close on or about December 12, 2025.

#ENVB Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

3 months ago

Prism M☀️rning M☀️vers
Premarket Gainers:
SaverOne 2014 Ltd. ( #SVRE) UP +225%
A SPAC III Acquisition ( #ASPC) up +157%
Enveric Bio ( #ENVB) up +98%
Beasley Broadcast Group ( #BBGI) up +76%

Premarket Decliners:
Turtle Beach Corporation ( #TBCH) down 5%,
Boundless Bio, Inc. ( #BOLD) down 5%,

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Most Searched, Wednesday December 10, 2025 – Crystal Equity Research

Most searched small-cap stocks, Wed Dec 10th - #POM #ENVB #DNN #NXDR #IBIO #PLUG #WRBY #TMC #RDW #SBET #PSIX #PARR #ONDS #MIGI #IRBT #HUN #FLWS #QUBT #BIAF #RR - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #GEV #CHWY #AFJK #JPM #ENVB #BEAT #GME #PLAB #CBRL #NEM

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates Enveric Biosciences (NASDAQ: ENVB) received a Notice of Allowance from the USPTO on December 9, 2025 for a patent application covering its EVM301 Series of molecules titled “N-heterocycle substituted tryptamine derivatives and methods of using.”The allowance will add to Enveric’s patent portfolio, covering compositions and methods of use for additional neuroplastogenic, non-hallucinogenic molecules and is described as reinforcing intellectual property around lead asset EB-003, which the company says is designed to engage 5-HT2A and 5-HT1B receptors to provide fast-acting antidepressant and anxiolytic effects while minimizing hallucinogenic effects.

#ENVB Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates Enveric Biosciences, a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application pertaining to its EVM401 Series of molecules being...

#ENVB Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results Enveric Biosciences (NASDAQ: ENVB) reported Q3 2025 results and operational progress toward an IND for lead candidate EB-003. Key clinical and CMC milestones include completion of pre-IND dose range finding studies establishing a maximum tolerated dose, positive preclinical PTSD model data (significant reduction in context-induced freezing, p < 0.05), receipt of an FDA written response to a pre-IND meeting request, and production of a 1-kilogram pharmaceutically compatible salt batch to support IND-enabling work.Corporate actions: issued and pursued patents, hired outside counsel to defend U.S. Patent No. 12,138,276, relocated headquarters to Cambridge, MA, completed warrant exercises generating approximately $2.2 million gross, completed a reverse 1-for-12 stock split after a Nasdaq bid-price deficiency, and reported Q3 net loss of $3.4 million with $3.8 million cash as of September 30, 2025.

#ENVB Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

JUST IN: ( NASDAQ: #ENVB ) US Companies Moving the Markets, Evening edition <br>Mon, Nov 03, 2025 as of 4:00 pm ET

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Enveric Biosciences Announces Reverse Stock Split Enveric Biosciences (NASDAQ: ENVB) will effect a 1-for-12 reverse stock split, effective at 8:00 a.m. New York time on October 28, 2025. The company received a Nasdaq delisting determination on October 22, 2025 related to minimum bid price, and the Board approved the 1-for-12 ratio under a previously authorized 1-for-5 to 1-for-50 range.The reverse split will convert every 12 pre-split shares into one post-split share, reduce outstanding common stock from 6,219,568 to approximately 518,297 shares, and apply proportional adjustments to equity awards and warrants. Fractional shares will be rounded up to whole shares.

#ENVB Enveric Biosciences Announces Reverse Stock Split

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance Enveric Biosciences (NASDAQ: ENVB) announced issuance of its 23rd U.S. patent from the USPTO, U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives.”The patent covers a unique series of neuroplastogenic small-molecule compounds designed to target key serotonin receptors and promote neuroplasticity, expanding Enveric’s intellectual property footprint and supporting potential pipeline expansion for treatments of psychiatric and neurological disorders.

#ENVB Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities Enveric Biosciences (NASDAQ: ENVB) announced on October 14, 2025 that its Board authorized the Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities.Any DAT opportunities would require further review and approval by the full Board. The company said this initiative is intended to enhance shareholder value and support long-term growth while it remains committed to advancing its core biotechnology programs. The company will provide updates as developments occur.

#ENVB Enveric Biosciences to Explore Digital Asset Treasury Opportunities

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

1-Kilogram Breakthrough: Enveric Bio's Mental Health Drug EB-003 Reaches Critical Manufacturing Milestone Biotech firm completes CMC milestones for EB-003 neuropsychiatric drug, including 1kg batch production and scalable synthesis. Advances toward IND filing and clinical trials for 5-HT1B/2A treatment.

#ENVB Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

$2.2 Million Capital Raise: Biotech Enveric Biosciences Completes Strategic Warrant Exercise Deal Biotech firm Enveric Biosciences secures $2.2M through warrant exercise at $0.915/share, issues new Series C and D warrants. Proceeds to fund product development and working capital.

#ENVB Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

First-Ever Microbial MDMA Production Method: Enveric Biosciences Breakthrough Could Transform Drug Discovery Biotech firm publishes groundbreaking research on microbial production of MDMA and 279 tryptamine derivatives. Novel approach bypasses traditional synthesis for psychiatric drug development.

#ENVB Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

FDA Streamlines Path: Enveric's Novel Depression Drug EB-003 Gets Green Light for Direct IND Filing Biotech firm Enveric Biosciences to submit IND for EB-003, a non-hallucinogenic depression/anxiety treatment, in early 2026. Company holds 26 US patents with 60 pending applications.

#ENVB Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Biotech Innovator Enveric Biosciences Joins Cambridge Hub, Advancing Novel Brain Drug EB-003 Biotech firm Enveric relocates to Cambridge, MA to advance EB-003 neuroplastogen drug development. Plans 2026 first-in-human trials for psychiatric disorders with dual 5-HT receptor targeting.

#ENVB Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Novel Non-Hallucinogenic Mental Health Drug EB-003 Passes Critical Safety Test for Depression & PTSD Biotech firm Enveric completes 7-day toxicology studies for EB-003, a first-in-class neuroplastogen targeting depression and PTSD. Drug shows brain penetration and oral bioavailability.

#ENVB Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Enveric Biosciences (NASDAQ:ENVB) reported Q2 2025 financial results and significant progress in its neuroplastogenic drug development programs. The company's lead candidate, EB-003, demonstrated a novel dual mechanism of action targeting both 5-HT₂A and 5-HT₁B receptors, positioning it as a first-in-class therapeutic for mental health conditions.Key developments include positive preclinical results in PTSD and chronic depression models, with EB-003 showing rapid extinction of fear responses and significant reduction in behavioral despair. The company is advancing toward an IND submission in early 2026. Financial results showed a net loss of $2.5 million for Q2 2025, with cash reserves of $2.8 million and additional fundraising of $4.9 million in H1 2025.Enveric also strengthened its IP portfolio with new patent grants and allowances across multiple chemical classes, reinforcing its position in non-hallucinogenic neuroplastogenic compounds.

#ENVB Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series Enveric Biosciences (NASDAQ: ENVB) has secured a second U.S. patent allowance for its EVM401 Series, covering novel methylone-inspired compounds designed for mental health treatment. The patent, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," focuses on non-hallucinogenic benzodioxole derivatives engineered to modulate neurotransmitters for neuropsychiatric disorders.The compounds are structurally similar to methylone, which has shown positive Phase 2 results in PTSD treatment, but feature unique chemical structures enabling patent protection and potential repeat-dose outpatient care. Unlike methylone, which lacks composition patent exclusivity, Enveric's molecules are fully patentable and proprietary. The company will conduct further preclinical testing to evaluate safety, pharmacokinetics, and effectiveness against PTSD.

#ENVB Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD) Enveric Biosciences (NASDAQ: ENVB) announced positive preclinical results for its lead drug candidate EB-003 in a PTSD model. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior (p The research, conducted by a third-party lab, utilized a well-established translational rodent model. CEO Joseph Tucker highlighted that current FDA-approved PTSD treatments (SSRIs) achieve only 20-30% full remission rates with delayed onset of benefits. EB-003, as a next-generation neuroplastogen, shows potential to enhance hippocampal neuroplasticity without causing hallucinations, potentially offering a breakthrough in PTSD treatment.

#ENVB Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 Enveric Biosciences (NASDAQ: ENVB) has announced new data revealing that its lead candidate EB-003 acts as an agonist of the serotonin receptor 5-HT1B, expanding its potential therapeutic applications. The compound demonstrated agonism of 5-HT1B with an EC50 of 110 nM, complementing its known partial agonist activity on the 5-HT2A receptor.This discovery broadens EB-003's potential applications to include major depressive disorder, Parkinson's disease, migraines, and cluster headaches. The drug candidate is currently in preclinical development, with IND-enabling activities planned through 2025. Previous data had shown positive pharmacology, in vitro safety, and oral bioavailability, including therapeutically relevant brain exposure in rodent models.

#ENVB Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Enveric CEO Showcases Groundbreaking Brain Disorder Treatments at Major BIO Convention Discover how Enveric's innovative neuroplastogenic therapeutics are advancing psychiatric treatment. CEO presents development strategy to investors. Get Details.

#ENVB Enveric Biosciences Announces Participation in 2025 BIO International Convention

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders Enveric Biosciences (NASDAQ: ENVB) has received a USPTO Notice of Allowance for a patent application covering novel aminated tryptamine derivatives, marking a significant advancement in non-hallucinogenic psychedelic-inspired therapeutics. The compounds, designed through Enveric's proprietary platform, demonstrated minimal hallucinogenic effects in preclinical testing, showing low Head Twitch Response and reduced 5-HT2A receptor activation. These therapeutics are specifically designed for frequent, outpatient dosing, targeting conditions like depression, anxiety, PTSD, and cognitive impairment. The patent covers both molecular compositions and therapeutic applications, strengthening Enveric's position in developing next-generation neuroplastogenic treatments that align better with patient lifestyles and clinical workflows.

#ENVB Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Breakthrough Patent: Enveric's New Sleep Drug Compounds Target Multi-Billion Dollar Market New patent covers MT1 receptor-targeting compounds for sleep and CNS disorders. Expands drug discovery platform into multi-billion dollar therapeutic market. See development pipeline.

#ENVB Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 Enveric Biosciences (NASDAQ: ENVB) has announced positive preclinical results for its lead drug candidate EB-003 in treating severe chronic depression. The drug demonstrated statistically significant improvements in the Open Space Forced Swim Test, a preclinical mouse model. At an oral dose of 30 mg/kg, EB-003 significantly reduced depression-like behavior within 30 minutes, showing comparable effects to Imipramine, an approved antidepressant.The study confirmed the efficacy of the 30 mg/kg dose and revealed no adverse locomotor effects. Additionally, a 22-day daily dosing trial showed no adverse behavioral, physiological, or neurological effects, supporting its safety for long-term use. EB-003 is part of Enveric's EVM301 Series, designed to stimulate synaptic plasticity without hallucinogenic effects.

#ENVB Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease Enveric Biosciences, a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules...

#ENVB Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

www.stocktitan.net/news/ENVB/enveric-biosci...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon May 19th - #NLSP #MDB #MDCX #ENVB #DVLT #TNGX #QMCO #NVAX #LAES #KTCC #INV #GAN #FTEK #FENC #CXAI #BCLI #AGAE #SOC #PGRE - More: crystalequityresearch.com/SmCpStr/ - #smallcap